Novo Nordisk Invests $65 Million to Expand US Finished-Products Mfg Plant
Novo Nordisk plans to invest $65 million to expand its finished-products manufacturing facility at its Clayton, Johnston County, North Carolina campus. This is the company’s third expansion at the site since 2010.
The expansion comes less than two years after the company broke ground on a $2-billion facility nearby that is expected to produce active pharmaceutical ingredients (API) for a range of current and future Type II diabetes medications and insulins. That facility is expected to employ an additional 700 biomanufacturing workers. The API facility, announced in August 2015, is on track to be completed by 2021.
Novo Nordisk currently employs over 1,000 manufacturing workers in Johnston County, North Carolina and says it is likely to hire almost two dozen additional employees to staff its finished products manufacturing facility, which is responsible for the formulation, filling, inspection, assembly, and packaging of diabetes and obesity medicines.
Novo Nordisk’s finished products facility in Clayton dates to 1993. In 2010, it launched a 120-job expansion there as part of a business partnership with Nypro, a plastics manufacturer.
